Efficacy and tolerance of mefloquine treatment for infants and children in Plasmodium falciparum malaria;Efficacité et tolérance de la méfloquine dans le traitement du paludisme à Plasmodium falciparum du nourrisson et de l'enfant

Archives de Pediatrie

Volumn 10, Issue 1, 2003, Pages 25-30

  Dubos, F ^a,b   Delattre, P ^a   Demar, M ^c   Carme, B ^c  

^a CENTRE HOSPITALIER DE CAYENNE   (French Guiana)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Centre Hospitalier de Cayenne   (Guyana)

Author keywords

Child; Malaria; Mefloquine

Indexed keywords

HALOFANTRINE; MEFLOQUINE; QUININE;

ADOLESCENT; ARTICLE; BODY WEIGHT; CHILD; CLINICAL FEATURE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; ENDEMIC DISEASE; FEMALE; FRENCH GUIANA; GASTROINTESTINAL SYMPTOM; HUMAN; INFANT; INSOMNIA; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MEDICAL LITERATURE; NONHUMAN; PARASITISM; PLASMODIUM FALCIPARUM; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TIME; TREATMENT FAILURE; TREATMENT OUTCOME; VALIDATION PROCESS; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 12244293380     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(03)00217-3     Document Type: Article

References (30)

1. OMS, communiqué du 25 avril 2000, OMS/28.
2. OMS, communiqué du 7 mai 1997, OMS/38.
3. Rapport du SDD (service départemental de désinfection) de Guyane à la PAHO (Pan American Health Organization), année 1999.
4. Carme B. Les parasitoses humaines en Guyane française. Presse Med 2001;30:1601-8.
5. Marsh K, Forster D, Warniru C, Mwangi I, Winstanley M, Marsh V, et al. Indicators of life-threatening malaria in African children?. N Eng J Med 1995;332:399-404.
6. Palmer KJ, Holliday SM, Brogden RN, Mefloquine, A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1993;45:430-75.
7. Luxemburger C, Price RN, Nosten F, Ter Kuile FO, Chongsuphajaisiddhi T, White NJ. Mefloquine in infants and young children. Ann Trop Paediatr 1996;16:281-6.
8. OMS, Évaluation de l'efficacité thérapeutique des antipaludiques pour le traitement du paludisme non compliqué à P. falciparum dans les régions de transmission élevée, 1996, WHO/MAL/96.1077.OMS Genève.
9. Nosten F, Ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, et al. Cardiac effects of anti-malarial treatment with halofantrine. Lancet 1993;341:1054-6.
10. Castor A, Rapoport P, Le Coz P. Prolonged QT interval with halofantrine. Lancet 1993;341:1541.
11. Touze JE, Bernard J, Keundjian A, Imbert P, Viguier A, Chaudet H, et al. Electrographic changes and halofantrine plasma level during acute falciparum malaria. Am J Trop Med Hyg 1996;54:225-8.
12. Matson PA, Luby SP, Redd SC, Rolka HR, Meriwether RA. Cardiac effects of standard-dose halofantrine therapy. Am J Trop Med Hyg 1996;54:229-31.
13. Di Perri G, Olliaro P, Ward S, Allegranzi B, Bonora S, Concia E. Rapid absorption and clinical effectiveness of intragastric mefloquine in the treatment of cerebral malaria in African children. J Antimicrob Chemotherap 1999;44:573-6.
14. Ter Kuile FO, Dolan G, Nosten F, Edstein MD, Luxemburger C, Phaipun L, et al. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet 1993;341:1044-9.
15. Supanaranond W, Suputtamongkol Y, Davis TM, Pukrittayakamee S, Teja-Isavatharm P, Webster HK, et al. Lack of significant adverse cardiovascular effect of combined quinine and mefloquine therapy for uncomplicated malaria. Trans R Soc Trop Med Hyg 1997;91:694-6.
16. Davis TM, Dembo LG, Kaye-Eddie SA, Hewitt BJ, Hislop RG, Batty KT, et al. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind placebo controlled trial. Br J Clin Pharmacol 1996;42:415-21.
17. Loathavorn P, Karbwang J, Na-bangchang K, Bunnag D, Harinasuta T. Effect of mefloquine on electrocardiographic changes in uncomplicated falciparum malaria patients. Southeast Asian J Trop Med Public Health 1992;23:51-4.
18. OMS, Résistance des parasites du paludisme aux médicaments, 1965, Série de rapports techniques No 296, OMS Genève.
19. Nosten F, Ter Kuile FO, Chonsuphajaisiddhi T, Na Bangchang K, Karbwang J, White NJ, et al. Mefloquine pharmacokinetics and resistance in children with acute falciparum malaria. Br J Clin Pharmacol 1991;31:556-9.
20. Sowunmi A, Oduola AMJ. Open comparison of mefloquine, mefloquine/sulfadoxine/pyrimethamine and chloroquine in acute uncomplicated falciparum malaria in children. Trans R Soc Trop Med Hyg 1995;89:303-5.
21. Singhasivanon V, Chonsuphajaisiddhi T, Sabcharoen A, Attanath P, Webster HK, Wernsdorfer WH, et al. Pharmacokinetics of mefloquine in children aged 6 to 24 months. Eur J Drug Metab Pharmacokinet 1992;17:275-9.
22. Conférence de consensus, texte long. Med Mal Infect 1999;29(suppl. 2):115-41.
23. Ter Kuile FO, Nosten F, Luxemburger C, Kyle D, Teja-Isavatharm P, Phaipun L, et al. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull World Health Organ 1995;73:631-42.
24. Slutsker LM, Khoromana CO, Payne D, Allen CR, Wirima JJ, Heymann DL, et al. Mefloquine therapy for plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome. Bull World Health Organ 1990;68:53-9.
25. Franssen G, Rouveix B, Lebras J, Bauchet J, Verdier F, Michon C, et al. Devided-dose kinetics of mefloquine in man. Br J Clin Pharmacol 1989;28:179-84.
26. Ketrangsee S, Vijaykadja S, Yamokgul P, Jatapadma S, Thimasarn K, Rooney W. Comparative trial on the response of P. falciparum to halofantrine and mefloquine in Trat Province, Eastern Thailand. Southeast Asian J Trop Med Public Health 1992;23:55-8.
27. Tin F, Hlaing N, Lasserre R. Single-dose treatment of falciparum malaria with mefloquine: field studies with different doses in semi-immune adults and children in Burma. Bull World Health Organ 1982;60:913-7.
28. Reisinger EC, Horstman RD, Dietrich M. Tolerance of mefloquine alone and in combination with sulfadoxine-pyrimethamine in the prophylaxis of malaria. Trans R Soc Trop Med Hyg 1989;83:474-7.
29. Lavallée I, Marc E, Moulin F, Tréluyer JM, Imbert P, Gendrel D. Troubles du rythme et allongement de l'espace QT sous halofantrine. Arch Pediatr 2001;8:795-800.
30. McBride SR, Lawrence CM, Pape SA, Reid CA. Fatal toxic epidermal necrolysis associated with mefloquine antimalarial prophylaxis. Lancet 1997;349:101.